Beryl Drugs standalone net profit declines 16.67% in the June 2017 quarter

Image
Capital Market
Last Updated : Jul 08 2017 | 12:01 AM IST

Sales rise 59.54% to Rs 4.85 crore

Net profit of Beryl Drugs declined 16.67% to Rs 0.10 crore in the quarter ended June 2017 as against Rs 0.12 crore during the previous quarter ended June 2016. Sales rose 59.54% to Rs 4.85 crore in the quarter ended June 2017 as against Rs 3.04 crore during the previous quarter ended June 2016. ParticularsQuarter EndedJun. 2017Jun. 2016% Var.Sales4.853.04 60 OPM %5.579.54 -PBDT0.230.24 -4 PBT0.130.14 -7 NP0.100.12 -17

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 07 2017 | 5:44 PM IST

Next Story